| 1 |
34773342 | PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. | 2022 Feb |
3 |
| 2 |
35064817 | Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. | 2022 May |
1 |
| 3 |
35083874 | BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer. | 2022 Jan |
1 |
| 4 |
35133214 | Pericardial effusion with pembrolizumab. | 2022 Feb 8 |
1 |
| 5 |
35261780 | Cisplatin plus anti-PD-1 antibody enhanced treatment efficacy in advanced esophageal squamous cell carcinoma. | 2022 |
2 |
| 6 |
35354691 | Increased PD-L1 Expression in Acquired Cisplatin-Resistant Lung Cancer Cells via Mir-181a. | 2022 May 25 |
1 |
| 7 |
35547095 | Current status and advances of immunotherapy in nasopharyngeal carcinoma. | 2022 |
1 |
| 8 |
33141317 | PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. | 2021 May |
2 |
| 9 |
33236151 | miR‑576‑3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD‑L1 and cyclin D1. | 2021 Jan |
1 |
| 10 |
33386467 | Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers. | 2021 Jun |
1 |
| 11 |
33399074 | The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. | 2021 Feb |
1 |
| 12 |
33416094 | FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis. | 2021 Feb |
2 |
| 13 |
33574678 | Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study. | 2021 |
2 |
| 14 |
33581579 | PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression. | 2021 May |
3 |
| 15 |
33626233 | Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. | 2021 Mar |
1 |
| 16 |
33799514 | Biomarker-Oriented Therapy in Bladder and Renal Cancer. | 2021 Mar 11 |
2 |
| 17 |
33878452 | Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway. | 2021 Jun |
2 |
| 18 |
33933375 | Retraction notice to "FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells" [BBA - Molecular and Cell Biology of Lipids 1863/3 (March 2018) 313-322]. | 2021 Aug |
1 |
| 19 |
34058473 | Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer. | 2021 Jul 23 |
1 |
| 20 |
34190696 | Camrelizumab plus Zoledronic Acid Showed Sustained Efficacy in a Patient with Cranial and Spinal Metastases from Lung Adenocarcinoma. | 2021 Jun |
1 |
| 21 |
34321456 | miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1. | 2021 Jul 28 |
6 |
| 22 |
34346116 | PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. | 2021 Nov |
3 |
| 23 |
34400305 | Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug. | 2021 Nov |
5 |
| 24 |
34411338 | Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer. | 2021 Nov |
4 |
| 25 |
34469060 | Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1. | 2021 Oct |
3 |
| 26 |
34486197 | HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma. | 2021 Dec |
6 |
| 27 |
34670665 | [Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway]. | 2021 Oct |
6 |
| 28 |
34686187 | Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions. | 2021 Oct 23 |
1 |
| 29 |
34710507 | A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody. | 2021 Dec |
1 |
| 30 |
35265629 | BCL2A1 and CCL18 Are Predictive Biomarkers of Cisplatin Chemotherapy and Immunotherapy in Colon Cancer Patients. | 2021 |
1 |
| 31 |
31777260 | MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. | 2020 Jan |
1 |
| 32 |
31814556 | Ginsenoside Rh2 Improves the Cisplatin Anti-tumor Effect in Lung Adenocarcinoma A549 Cells via Superoxide and PD-L1. | 2020 |
3 |
| 33 |
31821542 | Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. | 2020 Apr |
7 |
| 34 |
31853007 | PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma. | 2020 Mar |
7 |
| 35 |
32019287 | Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. | 2020 Apr |
2 |
| 36 |
32024543 | Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. | 2020 Feb 5 |
1 |
| 37 |
32068166 | STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. | 2020 May |
1 |
| 38 |
32259868 | [Systemic therapy for metastatic urothelial carcinoma - Current status and what comes after checkpoint inhibitors?] | 2020 Aug |
1 |
| 39 |
32468092 | [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments]. | 2020 Jul |
2 |
| 40 |
32493336 | Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy. | 2020 Jun 3 |
1 |
| 41 |
32517311 | Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study. | 2020 Jun 7 |
2 |
| 42 |
32591993 | HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line. | 2020 Oct |
1 |
| 43 |
32746878 | Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). | 2020 Aug 3 |
1 |
| 44 |
33011625 | Controlling the reactivity of [Pd(II)(N^N^N)Cl]+ complexes using 2,6-bis(pyrazol-2-yl)pyridine ligands for biological application: Substitution reactivity, CT-DNA interactions and in vitro cytotoxicity study. | 2020 Dec |
1 |
| 45 |
33038371 | Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment. | 2020 Dec 1 |
2 |
| 46 |
33046869 | Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. | 2020 Dec |
1 |
| 47 |
33243934 | Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. | 2020 Nov |
1 |
| 48 |
33269718 | [Current treatment options and future perspectives on first line metastatic bladder cancer.] | 2020 Dec |
1 |
| 49 |
30582240 | PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial. | 2019 May |
1 |
| 50 |
30606990 | Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer. | 2019 |
1 |